Sanofi (SNY)
| Market Cap | 110.18B -15.8% |
| Revenue (ttm) | 57.89B +11.0% |
| Net Income | 4.74B -54.2% |
| EPS | 1.90 -53.2% |
| Shares Out | 1.20B |
| PE Ratio | 24.30 |
| Forward PE | 9.34 |
| Dividend | $2.42 (5.25%) |
| Ex-Dividend Date | May 4, 2026 |
| Volume | 5,519,590 |
| Open | 46.43 |
| Previous Close | 47.12 |
| Day's Range | 44.93 - 46.61 |
| 52-Week Range | 39.07 - 50.61 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 54.92 (+19.24%) |
| Earnings Date | Oct 30, 2026 |
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia ... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $54.92, which is an increase of 19.24% from the latest price.
News
Sanofi Reportedly Gears Up For The Biggest Biotech Deal In Years
Insmed stock surged Thursday on a rumored bid from French pharma giant Sanofi. The deal would be one of the largest in recent history.
Insmed deal makes ‘considerable strategic sense’ for Sanofi, says BMO Capital
After Bloomberg reported that Sanofi (SNY) is evaluating a potential acquisition of Insmed (INSM), BMO Capital analyst Conor MacKay argued that adding Insmed’s differentiated respiratory growth engine...
As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments
An ongoing shortage of Sanofi’s Pompe disease treatment is forcing some patients to miss critical doses. They worry their health is at risk.
30% premium for Insmed ‘not out of reach’ for Sanofi, says Jefferies
Jefferies notes Bloomberg reported that Sanofi (SNY) is considering acquiring Insmed (INSM), which is currently valued at about $27B. Given that Sanofi’s CFO has suggested that large acquisitions are ...
Insmed’s strategic value in focus amid rumored Sanofi bid, says Raymond James
Raymond James reiterates an Outperform rating on Insmed (INSM) shares. Sanofi (SNY) is reportedly exploring an acquisition of Insmed, though discussions remain preliminary with no formal offer, reinfo...
Mizuho doesn’t believe Insmed ready to sell
Mizuho analyst Graig Suvannavejh notes Insmed (INSM) shares were up as much as 20% intraday following Bloomberg’s report that Sanofi (SNY) is weighing an acquisition of the company. Insmed has…
Insmed Stock Already Was Flying High. Sanofi Takeover Buzz Lights the Afterburners.
Insmed stock jumps following a report saying Sanofi is eyeing a takeover of the biopharma company.
Sanofi considering takeover of Insmed, Bloomberg reports
10:06 EST Sanofi (SNY) considering takeover of Insmed (INSM), Bloomberg reports
Insmed jumps 8% after Bloomberg report on Sanofi takeover interest
10:07 EST Insmed (INSM) jumps 8% after Bloomberg report on Sanofi (SNY) takeover interest
Sanofi eyeing takeover of U.S. drugmaker Insmed, Bloomberg reports
Sanofi (SNY) is exploring a potential acquisition of U.S. drugmaker Insmed (INSM), which could rank among the largest biopharma deals in recent years, Bloomberg’s Michelle F. Davis, David Carnevali, R...
Jacobs selected by Sanofi as EPCM partner for new insulin manufacturing facility
Jacobs (J) has been selected by Sanofi (SNY) as the engineering, procurement and construction management, or EPCM, partner for a new insulin manufacturing facility in Frankfurt, Germany. Located along...
Jacobs selected by Sanofi to deliver new insulin manufacturing facility in Germany
DALLAS--(BUSINESS WIRE)-- #OurJacobs--Jacobs selected by Sanofi as the EPCM partner for a new insulin manufacturing facility in Frankfurt, Germany.
Sanofi's VaxRabeo Approved In Europe For Rabies Prevention Across All Groups
(RTTNews) - Sanofi (SNY) announced that the European Commission has approved VaxRabeo, its next-generation rabies vaccine, for both pre-exposure and post-exposure and post-exposure prophylaxis in peop...
Press Release: Sanofi's next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
Sanofi's next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages Paris, November 19, 2026. Sanofi announced today that the European Commission has approved VaxRabeo (rabies virus ina...
Sanofi Wins First U.S. Approval For Neurological Symptoms Of Type 3 Gaucher Disease
(RTTNews) - Sanofi announced that the U.S. FDA has approved Infilbray (venglustat) for the treatment of neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 1...
Press Release: Sanofi's Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease
Sanofi's Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease
US FDA approves Sanofi's genetic disorder drug
The US FDA on Wednesday approved Sanofi's oral drug venglustat, making it the first treatment for a type of rare genetic condition that affects the brain and nervous system, the health regulator sai...
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi's development of a combination COVID...
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
Analysts Think These Stocks Could More Than Double in ValueNovavax (NASDAQ:NVAX) is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and su...
Sanofi Transcript: Jefferies Global Healthcare Conference
Vaccine strategy pairs global scale with renewed innovation, including combination vaccines and candidates aimed at new markets. Key milestones include flu-COVID phase III results within 18 months, PCV21 results in 2027 and an acne vaccine readout targeted for 2028.
Sanofi Advances Public Access To Sarclisa For Newly Diagnosed Multiple Myeloma Patients In Canada
(RTTNews) - Sanofi SA (SNY) announced the successful completion of negotiations with Canada's pan-Canadian Pharmaceutical Alliance (pCPA), marked by a signed Letter of Intent (LOI) for Sarclisa (isatu...
DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
Seawolf Therapeutics on Monday launched publicly with $100 million in funding and a deal with French drugmaker Sanofi worth up to $1.2 billion, as it seeks to develop DNA-based medicines.
Rugby centre Henry Slade and his father look back: ‘I’d seen my dad live with diabetes, so my diagnosis wasn’t as upsetting as it might have been’
The England player on finding out he had type 1, the wonder of Jelly Babies, and the sacrifices his parents made for him Born in Plymouth, Devon, in 1993, Henry Slade is a centre for Exeter Chiefs and...
Sanofi price target raised to EUR 93 from EUR 78 at Citi
Citi analyst Graham Parry raised the firm’s price target on Sanofi (SNY) to EUR 93 from EUR 78 and keeps a Neutral rating on the shares.
The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment
Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.